ARGX

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

Argenx Sets Sept 17 EGM to Vote on Two New Board Directors

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Argenx announced an Extraordinary General Meeting for Sept 17, 2026 in Amsterdam to vote on two new non-executive directors, Thomas Brakel and Khurem Farooq. The notice highlights e-voting and proxy options with convocation details on argenx.com and ABN Amro’s evoting site. While governance updates are typically modest for ARGX, the outcome could influence board oversight and strategic discussions.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Argenx to hold EGM Sept 17, 2026 at 15:00 CEST; directors on agenda.</li><li>Thomas Brakel and Khurem Farooq nominated as non-exec directors.</li><li>Shareholders to vote by proxy; e-voting details on argenx site.</li><li>Notice of convocation available on argenx.com and ABN Amro evoting.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>argenx SE (ARGX)</strong>: Announces EGM for Sept 17 to vote on two non-exec directors; governance event.</li><li><strong>ABN AMRO Bank N.V. (ABN.AS)</strong>: Provides evoting link for convocation; potential minor Dutch-market focus around the vote.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This is a Corporate Developments piece focused on governance. The event is leadership-change oriented, marking board refresh activity rather than operational or clinical milestones.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>EGM date Sept 17 could trigger short-term price volatility.</li><li>Two new non-exec directors could influence governance signals.</li><li>Proxy/e-voting mechanics may impact turnout-related price moves.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date/time: September 17, 2026 at 15:00 CEST.</li><li>Venue: Freshfields LLP, Amsterdam.</li><li>Agenda: appointment of Thomas M. Brakel and Khurem Farooq as non-exec directors.</li><li>Notice of convocation available on argenx.com and ABN Amro evoting.</li><li>Argx is listed on Euronext and NASDAQ as ARGX.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral near-term; a favorable board appointment could provide modest upside within 1–3 months.</p>
  </section>
</section>


<article>
  <h2>argenx Announces Extraordinary General Meeting of Shareholders on September 17, 2026</h2>

  <section>
    <p><strong>August 3, 2026 – 22:01 PM CEST</strong> | Amsterdam, the Netherlands — argenx SE (<strong>Euronext & NASDAQ: ARGX</strong>), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will be held at <strong>15:00 CEST</strong> on <strong>Thursday, September 17, 2026</strong> at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.</p>

    <p>The shareholders and all other persons entitled to attend the Extraordinary General Meeting are invited to attend. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.</p>
  </section>

  <section>
    <h3>Agenda and Voting Items</h3>
    <p><em>The two voting items on the agenda</em> will be the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non- executive directors of the Company’s Board of Directors.</p>
    <p>The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.</p>
  </section>

  <section>
    <h3>About argenx</h3>
    <p>argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on <em>LinkedIn</em>, <em>Instagram</em>, and <em>YouTube</em>.</p>
  </section>

  <section>
    <h3>Key Facts</h3>
    <ul>
      <li><strong>Stock symbol:</strong> ARGX (Euronext and NASDAQ)</li>
      <li><strong>Event type:</strong> Extraordinary General Meeting of Shareholders</li>
      <li><strong>Time:</strong> <strong>15:00 CEST</strong></li>
      <li><strong>Date:</strong> <strong>September 17, 2026</strong></li>
      <li><strong>Location:</strong> Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands</li>
      <li><strong>Agenda:</strong> Appointment of two non- executive directors to the Board of Directors (Mr. Thomas M. Brakel and Mr. Khurem Farooq)</li>
      <li><strong>Documents:</strong> Agenda and ancillary documents available via the argenx website; available for inspection at the argenx offices</li>
      <li><strong>Copy of documents:</strong> legal@argenx.com</li>
      <li><strong>Voting:</strong> Electronic proxy option as referred to in the convocation</li>
    </ul>
  </section>

  <section>
    <h3>Contacts</h3>
    <p><strong>Media:</strong> Ben Petok — Bpetok@argenx.com</p>
    <p><strong>Investors:</strong> Alexandra Roy — aro y@argenx.com</p>
  </section>
</article>

Argenx announced an Extraordinary General Meeting for Sept 17, 2026 in Amsterdam to vote on two new non-executive directors, Thomas Brakel and Khurem Farooq. The notice highlights e-voting and proxy options with convocation details on argenx.com and ABN Amro’s evoting site. While governance updates are typically modest for ARGX, the outcome could influence board oversight and strategic discussions.

News insight

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

AI summary

Sentiment rationale

Key facts

Corporate Developments